Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Zenas Bio: Recent IPO With Late-Stage Candidate [Seeking Alpha]

Zenas BioPharma, Inc. (ZBIO) 
Company Research Source: Seeking Alpha
Follow Summary Zenas BioPharma, Inc.'s obexelimab targets CD19 and Fc?RIIb to modulate B-cells, aiming to treat multiple autoimmune diseases with fewer side effects. Phase 2 data for obexelimab in IgG4-RD showed strong clinical improvement and a high complete remission rate, with manageable adverse events. Zenas has a solid financial position post-IPO, with recent funding and a collaboration with Bristol-Myers Squibb, ensuring a decent cash runway. Despite the promising late-stage asset, I remain cautious due to the uncertainties surrounding recent IPOs and limited financial data. Pgiam/iStock via Getty Images Recently IPO-ed Zenas BioPharma, Inc. NASDAQ: ZBIO ) is developing obexelimab, a B-cell therapeutic targeting CD19 and Fc?RIIb. The molecule was acquired from Xencor ( XNCR ) in 2021 against an equity stake. Target indications are About the TPT service Thanks for reading. At the Total Pharma Tracker , we offer the following:- Our Android app and website feat Show less Read more
Impact Snapshot
Event Time:
ZBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ZBIO alerts
Opt-in for
ZBIO alerts

from News Quantified
Opt-in for
ZBIO alerts

from News Quantified